# Ajax's lead medicine is a once-daily pill in the early stages of study for myelofibrosis.

*biotech · news · 2026-04-27 · The Boston Globe*

## Key points

- Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion, including milestones.
- Ajax's lead drug is an early-stage, once-daily pill for myelofibrosis, with key data expected this year.
- The Ajax acquisition follows Lilly's $7 billion Kelonia buyout to access blood cancer gene therapies.
- Lilly was an original investor in Ajax and seeks to improve upon JAK2 inhibitor cancer medicines.

**Companies:** Eli Lilly & Co., Ajax Therapeutics Inc., Kelonia Therapeutics, Scorpion Therapeutics Inc., Point Biopharma, Emergence
**Countries:** United States

[Read the full story on The Boston Globe](https://www.bostonglobe.com/2026/04/27/business/eli-lilly-ajax-acquisition/)

---

Canonical: https://newsio.io/n/37dc7500-5f50-40ef-b73b-78f93757c144/ajaxs-lead-medicine-is-a-once-daily-pill-in-the-early-stages-of-study-for-myelof
Summarized by Newsio from The Boston Globe. https://newsio.io/how-it-works